Inventor
MATARAZA JENNIFER MARIE
US19 patents
⚠️ This page may combine multiple inventors who share the name “MATARAZA JENNIFER MARIE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
16 patentsUS9683048B2Jun 20, 2017
Antibody molecules to PD-1 and uses thereof
NOVARTIS AG115 citations98
US9815898B2Nov 14, 2017
Antibody molecules to PD-1 and uses thereof
NOVARTIS AG35 citations97
US9605070B2Mar 28, 2017
Antibody molecules to TIM-3 and uses thereof
NOVARTIS AG67 citations97
US10711060B2Jul 14, 2020
Antibody molecules to LAG-3 and uses thereof
NOVARTIS AG29 citations93
US9988452B2Jun 5, 2018
Antibody molecules to PD-L1 and uses thereof
NOVARTIS AG30 citations93
US9908936B2Mar 6, 2018
Antibody molecules to LAG-3 and uses thereof
NOVARTIS AG23 citations93
US10472419B2Nov 12, 2019
Antibody molecules to TIM-3 and uses thereof
NOVARTIS AG12 citations92
US9884913B2Feb 6, 2018
Antibody molecules to TIM-3 and uses thereof
NOVARTIS AG12 citations92
US10981990B2Apr 20, 2021
Antibody molecules to TIM-3 and uses thereof
NOVARTIS AG11 citations85
US11155620B2Oct 26, 2021
Method of detecting TIM-3 using antibody molecules to TIM-3
NOVARTIS AG6 citations83
US10851165B2Dec 1, 2020
Antibody molecules to PD-L1 and methods of treating cancer
NOVARTIS AG10 citations83
US10752687B2Aug 25, 2020
Antibody molecules to PD-1 and uses thereof
NOVARTIS AG6 citations83
US11827704B2Nov 28, 2023
Antibody molecules to PD-1 and uses thereof
NOVARTIS AG2 citations72
US11413340B2Aug 16, 2022
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
NOVARTIS AG2 citations72
US12186278B2Jan 7, 2025
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
NOVARTIS AG0 citations62
US12252535B2Mar 18, 2025
Antibody molecules to LAG-3 and uses thereof
NOVARTIS AG0 citations61